Your browser doesn't support javascript.
COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study.
Fano, Valeria; Coviello, Enzo; Consonni, Dario; Agresta, Alessandro; Orsini, Nicola; Crielesi, Alessia; Miglietta, Antonio Salvatore; Pasqua, Caterina; Vairo, Francesco; Vivaldi, Fabio; De Angelis, Giuseppe; Colaiocco, Giovanni; Fabiani, Massimo.
  • Fano V; Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.
  • Coviello E; Medical Doctor, Bari, Italy.
  • Consonni D; Epidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Agresta A; Regional Service for Epidemiology, Surveillance and Control of Infectious Diseases, Lazio Region, Italy.
  • Orsini N; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
  • Crielesi A; Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.
  • Miglietta AS; Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.
  • Pasqua C; Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.
  • Vairo F; Regional Service for Epidemiology, Surveillance and Control of Infectious Diseases, Lazio Region, Italy.
  • Vivaldi F; Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.
  • De Angelis G; Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.
  • Colaiocco G; Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.
  • Fabiani M; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Expert Rev Vaccines ; 21(8): 1147-1157, 2022 08.
Article in English | MEDLINE | ID: covidwho-1852791
ABSTRACT

BACKGROUND:

The waning of the protective effect of COVID-19 vaccines and timing of booster doses are debated.

METHODS:

Population-based cohort study in the largest Health-Authority of Lazio region, Italy, on 946,156 residents aged 12+ (study period 1 January 2021-10 January 2022). Vaccine effectiveness (VE) against any SARS-CoV-2 infection (symptomatic or asymptomatic) was estimated through multivariable negative-binomial models using unvaccinated person-time as a reference.

RESULTS:

The primary vaccination cycle was completed by 81% of residents; of these, 45% received a booster dose. Vaccine coverages were lower for foreigners, and people living in deprived areas, families with children aged 0-11, and households size 1 or 6+. Overall, VE waned from 71% (95% Confidence Interval (CI) 70-73%) 1 month after the second dose to 43% (CI 41-45%) after 4 months and 24% (CI 21-27%) after 6 months, especially in the elderly aged 70+. We observed a prompt restore of VE 15-19 days after the booster dose (69%, CI 67-70%).

CONCLUSIONS:

Our results support the recommendation of a booster dose 4 months after completion of the primary cycle, giving priority to elderly and fragile individuals. The lower vaccine coverage among social disadvantaged subgroups suggests the need of targeted communication and interventions.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Aged / Child / Humans Language: English Journal: Expert Rev Vaccines Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: 14760584.2022.2080057

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Aged / Child / Humans Language: English Journal: Expert Rev Vaccines Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: 14760584.2022.2080057